Global Reach FDNA’s AI-driven phenotyping platform is already used by 70% of the world’s clinical geneticists across 10,000 sites in over 130 countries, indicating a large potential enterprise customer base and opportunities for upsell with large hospital networks and research institutes.

Collaborative Network Strategic partnerships with ThinkGenetic, Ambry Genetics, and Guardian Research Network highlight a proven path for integrations and co-development with genetics laboratories, suggesting targeted outreach to labs seeking scalable diagnostic support and precision medicine capabilities.

Precision Medicine Fit FDNA’s focus on AI-powered precision medicine for diagnosing and treating genetic diseases presents cross-sell opportunities to hospitals and clinics expanding genomic testing panels, value-added decision support, and phenotypic-genotypic data analytics.

Data Asset leverage A deep, crowdsourced database linking phenotypic and genotypic information enables partnerships with research centers and biopharma for rare disease studies, clinical trials recruitment, and advanced diagnostic tool integrations.

Financial Scale With revenue in the low multi-million range and a lean employee base, FDNA appears primed for scalable deployments within mid to large health systems, enabling pilots, tiered pricing, and channel partnerships to accelerate adoption.